CRISPR & Cas Genes Market Players:
- Thermo Fisher Scientific
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Illumina
- Agilent Technologies
- Synthego
- Danaher
- Origene Technologies
- GenScript
- Lonza
- Revvity, Inc.
- Merck KGaA
- Mammoth Biosciences, Inc.
- Regeneron Pharmaceuticals, Inc.
Considering the higher utility in the medical industry, key players are majorly focused on engaging their offerings in the pharmaceutical segment in the CRISPR & cas genes market. They are actively developing new applications and therapeutics for wider adoption. For instance, in January 2024, CRISPR Therapeutics attained FDA approval for using CASGEVY (exagamglogene autotemcel) as a streamlined curative for transfusion-dependent beta-thalassemia. This CRISPR/Cas9 gene-edited cell therapy has been proven to be highly effective for residents aged 12 and over. Simultaneously, many other biopharmaceutical pioneers are participating in this cohort by introducing more efficient approaches. Such key players are CRISPR & cas genes market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of CRISPR & cas genes is assessed at USD 5.85 billion.
The global CRISPR & cas genes market size was valued at around USD 5.09 billion in 2025 and is projected to grow at a CAGR of more than 16.5%, reaching USD 23.44 billion revenue by 2035.
North America CRISPR & Cas genes market will dominate over 44.20% share by 2035, driven by genomic advancements and strategic collaborations.
Key players in the market include Thermo Fisher Scientific, Illumina, Agilent Technologies, Synthego, Danaher, Origene Technologies, GenScript, Lonza, Revvity, Inc., Merck KGaA, Mammoth Biosciences, Inc., Regeneron Pharmaceuticals, Inc.
